Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Aims To review the evolution and advancement of GLP‐1 receptor agonist (GLP‐1RA)
therapy, through the lens of randomised controlled trials, from differentiating characteristics …

Purpose The goal of this study was to assess the effect of glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes. Methods The …

Aims To study differences in clinical outcomes between initiating glucagon‐like peptide‐1
receptor agonist (GLP‐1 RAs) vs insulin treatment in patients with type 2 diabetes treated …

Background Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin
secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Treatment algorithms for type 2 diabetes call for intensification of therapy over time as the
disease progresses and glycaemic control worsens. If diet, exercise and oral …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2
diabetes mellitus, show promise in promoting weight loss and improving heart health in …